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Aim The aim of this study was to evaluate the benefits and safety of long-term i.v. iron therapy in iron-deficient patients with
heart failure (HF).
Methods
and results
CONFIRM-HF was a multi-centre, double-blind, placebo-controlled trial that enrolled 304 ambulatory symptomatic
HF patients with left ventricular ejection fraction ≤45%, elevated natriuretic peptides, and iron deficiency (ferritin
,100 ng/mL or 100–300 ng/mL if transferrin saturation ,20%). Patients were randomized 1 : 1 to treatment with i.v.
iron, as ferric carboxymaltose (FCM, n ¼ 152) or placebo (saline, n ¼ 152) for 52 weeks. The primary end-point was
the change in 6-min-walk-test (6MWT) distance from baseline to Week 24. Secondary end-points included changes in
New York Heart Association (NYHA) class, Patient Global Assessment (PGA), 6MWT distance, health-related
quality of life (QoL), Fatigue Score at Weeks 6, 12, 24, 36, and 52 and the effect of FCM on the rate of hospitalization
for worsening HF. Treatment with FCM significantly prolonged 6MWT distance at Week 24 (difference FCM vs.
placebo: 33+ 11 m, P ¼ 0.002). The treatment effect of FCM was consistent in all subgroups and was sustained to
Week 52 (difference FCM vs. placebo: 36+11 m, P, 0.001). Throughout the study, an improvement in NYHA
class, PGA, QoL, and Fatigue Score in patients treated with FCM was detected with statistical significance observed
from Week 24 onwards. Treatment with FCM was associated with a significant reduction in the risk of hospitalizations
for worsening HF [hazard ratio (95% confidence interval): 0.39 (0.19–0.82), P ¼ 0.009]. The number of deaths (FCM: 12,
placebo: 14 deaths) and the incidence of adverse events were comparable between both groups.
Conclusion Treatment of symptomatic, iron-deficient HF patients with FCM over a 1-year period resulted in sustainable improve-
ment in functional capacity, symptoms, and QoL and may be associated with risk reduction of hospitalization for worsen-
ing HF (ClinicalTrials.gov number NCT01453608).
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Introduction
With the constantly increasing prevalence and incidence, heart
failure (HF) has now become an epidemic problem carrying relevant
medical, social and economic consequences.1 Despite recent devel-
opments in HF management, the morbidity and mortality in this clin-
ical syndrome remain unacceptably high and many patients suffer
from debilitating symptoms adversely affecting their quality of
life.2 –4 Cardiovascular and non-cardiovascular co-morbidities
often complicate the natural course of HF with deleterious impact
on clinical status, symptoms, and HF progression, thus constituting
targets for potential intervention.2,5
Iron deficiency (ID) is one of the most common nutritional defi-
ciencies worldwide, affecting one-third of the general population.6
Several chronic disorders may be complicated by ID,6– 9 but only
recently ID has been also reported as a frequent co-morbidity in
stable HF patients regardless of ejection fraction10,11,12 and in
patients admitted to hospital due to worsening HF.13 Mechanisms
underlying the development of ID in HF have not been rigorously
investigated, but ID may be a consequence of impaired iron absorp-
tion, augmented gastro-intestinal loss, and reduced availability of util-
izable iron from the reticuloendothelial system.14 Heart failure
complicated with ID is associated with impaired functional capacity,
poor quality of life, and increased mortality.10,11,13 –15 Interestingly,
opposite to the traditional view, deleterious consequences of ID in
HF syndrome are irrespective of anaemia and other important con-
founders (e.g. age, severity of the disease, renal function).10 –15
Thus, correction of ID itself can be considered an attractive thera-
peutic target in HF, and this hypothesis has been recently tested in
a few clinical studies.14,16 These trials, however, suffer from several
drawbacks: the vastmajoritywas single-centre studieswith heteroge-
neous design (open-label vs. placebo-controlled, treating only
patients with anaemia vs. all ID patients, typically with short-duration
of therapy). While i.v. iron therapy in iron-deficient stable HF
patients14,16 appears beneficial, there are still uncertainties on the ap-
propriate use of iron in HF. In particular, these uncertainties include
longer-term sustainability of beneficial effects, safety, and potential
impact on outcomes. Thus, we designed the CONFIRM-HF (Ferric
CarboxymaltOse evaluatioN on perFormance in patients with
IRon deficiency in coMbination with chronic Heart Failure) to
address these questions.
Methods
Study design and oversight
Between September 2011 and February 2013, 304 eligible patients were
enrolled from 41 sites in 9 countries. The study design has been pub-
lished.17 The protocol was approved by the institutional review board
at each participating centre and conducted in accordance with the prin-
ciples of the Declaration of Helsinki (1996), International Conference on
Harmonization Good Clinical Practice, and local and national regulations.
Written informedconsent wasprovided byall patients prior to anystudy-
related procedures.
The trial was designed, implemented, and overseen by the Steering
Committee together with representatives of the sponsor, Vifor
Pharma Ltd., Glattbrugg, Switzerland. ClinStar (Moscow, Russia) was re-
sponsible for on-site monitoring of sites in Russia and Ukraine. ICON
(Dublin, Ireland) was responsible for on-site monitoring in other coun-
tries, in addition to data collection, data management, and data analysis.
All analyseswereperformed according toapre-defined statistical analysis
plan validated by the sponsor Vifor Pharma Ltd. An independent Data
Safety Monitoring Board, with no direct contact with the study site per-
sonnel nor with patients, reviewed safety data on an ongoing basis. The
independent Clinical Endpoint Committee adjudicated all hospitaliza-
tions and deaths. The manuscript was prepared and submitted for publi-
cation by the Steering Committee. The authors had access to the study
data and vouch for the accuracy and completeness of the reported ana-
lyses. The trial is registered at ClinicalTrials.gov, NCT01453608.
Participants
Eligible patients included stable ambulatory HF patients in New York
Heart Association (NYHA) class II or III, with left ventricular ejection frac-
tion (LVEF) ≤45%, elevated natriuretic peptides (brain natriuretic
peptide .100 pg/mL and/or N-terminal-pro-brain natriuretic peptide
.400 pg/mL), presence of ID [defined as serum ferritin level ,100 ng/
mL, or between 100 and 300 ng/mL if transferrin saturation (TSAT)
,20%] and haemoglobin (Hb) ,15 g/dL (all at the screening visit).
There was no lower limit for Hb, but subjects with an immediate need
for transfusion were excluded. All subjects must have been capable of
completing the 6 min walk test (6MWT). Patients with uncontrolled
hypertension, infection, clinical evidence of current malignancy, or signifi-
cantly impaired liver or renal function were excluded. There was no
upper age limit. All detailed inclusion/exclusion criteria are presented
in the design paper17 and in the protocol (see Supplementary material
online).
Randomization
At the baseline visit, prior to commencing treatment, clinical history,
physical examination, 12-lead electrocardiogram, assessment of NYHA
class, 6MWT, and health-related quality of life were obtained for each
patient. Randomization was achieved using a central interactive voice
responsesystemtoallocatepatients to treatment groupsand avoid selec-
tionbias. Eligiblepatientswere randomlyassigned in a1 : 1 ratio to receive
either i.v. iron or placebo (normal saline). Subjects were stratified by site
and by Hb levels (two strata: subjects with Hb ,12.0 g/dL vs. Hb
≥12.0 g/dL), stratification was incorporated into this study to help
ensure a balance of baseline Hb across treatment groups.
Therapy and blinding
Intravenous iron was given as ferric carboxymaltose solution [Ferinjectw/
Injectaferw Vifor Pharma (FCM)]. Study medication was given as un-
diluted bolus i.v. injections of 10 or 20 mL (which is the amount of
FCM that is equivalent to 500 or 1000 mg of iron, respectively) adminis-
tered over at least 1 min. Normal saline [0.9% weight/volume (w/v)
NaCl] was administered as placebo as per the instructions for active
therapy.
Study drug (FCM or placebo) was administered in doses based on
subject weight and Hb value at screening, according to the scheduled
dosing scheme (see the design paper17 and the protocol in the Supple-
mentary material online, Appendix for details). This included both
therapy dosing (correctionphase) and maintenance dosing (maintenance
phase). In summary, total FCM doses were between 500 and 2000 mg
iron FCM (or equivalent volume of placebo solution) in the therapy
phase (dosed at baseline and Week 6), and thereafter maintenance
FCM dosing of 500 mg iron (or equivalent volume of placebo solution)
at each of Weeks 12, 24, and 36, if ID was still present (criteria for ID
were re-assessed at each visit).
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Each administration of study drug occurred after completion of all ap-
plicable study-related assessments (including quality of life assessments
and collection of blood samples).
Ferric carboxymaltose is a dark brown and cannot easily be masked
from placebo (0.9% saline). Therefore, unblinded study personnel (at
least one physician) not involved in any study assessments for efficacy
or safety were responsible for preparing and administering the study
treatment injections in black syringes and using a curtain (or similar) to
maintain subject blinding. The central laboratory results on iron metab-
olism markers and Hb were sent only to the unblinded study personnel
who were responsible for evaluating these parameters for subsequent
dosing and/or other intervention, if applicable.
Study end-points
The primary end-point for the study was the change in 6MWT distance
from baseline to Week 24.
The details of 6MWT are presented in the protocol (see Supplemen-
tary material online) and in the design paper.17 In summary, subjects
were advised to take only a light meal and not to have undertaken
vigorous exercise within 2 h prior to the test. The 6MWTs were
planned to take place shortly after breakfast (i.e. early morning) or
lunch (i.e. early afternoon). All tests were performed along a flat,
straight corridor with a hard surface, at least 25 m long with turnaround
points marked by two chairs at each end of the measured course. Prior
to testing, vital signs were measured in a sitting position after a rest of
10 min and subjects completed the Fatigue Score (assessed using a
10-point visual analogue scale, ranging from 1 for no fatigue to 10 for
very severe fatigue). Subjects were instructed to walk the length of
the course at their own pace while attempting to cover as much
ground as possible in 6 min. The person supervising the 6MWT encour-
aged the subject verbally at frequent intervals. Subjects were allowed to
rest on the chairs during the test, but were encouraged to resume
walking as soon as they felt physically able to do so. The distance
walked in 6 min, to the nearest meter, was recorded. Every effort was
made to have the same member of the site supervising all 6MWTs for
a specific subject.
Secondary end-points included changes in NYHA class, Patient Global
Assessment (PGA), 6MWT distance, Fatigue Score and health-related
quality of life [evaluated using Kansas City Cardiomyopathy Question-
naire (KCCQ), European Quality of Life 5D (EQ-5D) questionnaire]
assessed at Weeks 6, 12, 24, 36, and 52. Additionally, the following sec-
ondary outcome-related end-points were assessed, in which deaths
were censored in the analysis of HF hospitalizations:17
† rate of any hospitalization, rate of hospitalization for any cardiovascu-
lar reason, and rate of hospitalization due to worsening HF;
† time to first hospitalization for any reason, time to first hospitalization
for any cardiovascular reason and time to first hospitalization due to
worsening HF;
† time to death for any reason, time to death for any cardiovascular
reason, and time to death due to worsening HF.
Standardized definitions for cause of death or hospitalization were devel-
oped by members of the independent Clinical Endpoint Committee of
CONFIRM-HF (for details see the design paper17. All such events were
recorded throughout the study and adjudicated by the Clinical Endpoint
Committee.
Additional secondary end-points were changes from baseline to
Weeks 6, 12, 24, 36, and 52 in clinical laboratory panels (haematology,
clinical chemistry, iron status, and cardiac biomarkers). Safety analysis
included serious and non-serious adverse events, assessed up to
Week 52.
Statistical analysis
The sample size calculation for CONFIRM-HF was based on the
expected change of 6MWT distance at Week 24, using the data reported
in the FAIR-HF study.18 The mean difference between groups in the
change of 6MWT distance from baseline at Week 24 in FAIR-HF was
29 m with a standard deviation (SD) of 72 m. Based on these assump-
tions, a sample size of 130 subjects per group (i.e. 260 patients in total)
were required to detect a mean treatment effect of at least 29 m at
Week 24 with 90% power using an alpha of 0.05 (two-sided). The
sample size was increased to 150 subjects per group (300 total) to
allow for some loss of information due to early study discontinuation.
The primary efficacy analysis was performed according to the
intention-to-treat principle (ITT) on the full-analysis set (FAS), including
all subjects whowere randomized and inwhom investigational drug treat-
ment was started, and with efficacy data returned. Subjects were analysed
according to the treatment group to which they were randomly assigned,
i.e. irrespective of actual treatment received. In addition supportive ana-
lysis will be performed on the per-protocol analysis set.
The primary efficacy end-point, change in 6MWT from baseline to
Week 24, included imputations for missing values from subjects who
were hospitalized at that time or had died. For hospitalized patients,
the worst non-null 6MWT result collected across the study was then
used for the analysis. For subjects who died, a value of 0 was imputed.
The primary efficacy analysis was conducted using an analysis of the co-
variance (ANCOVA) model on the change in 6MWT from baseline to
Week 24, with adjustment for baseline 6MWT distance, Hb level at
screening and country (Russia, Ukraine, Poland, and other European
countries) on the FAS.
Supportiveanalyseswereperformed using theper-protocol set (those
subjects included in the FAS without major protocol violations) and
observed cases (without imputation for subjects that were hospitalized
at the time or had died).
NYHA class missing values due to subjects who died were imputed
using the worst possible assessment of class V, and subjects hospitalized
during the planned assessment were attributed a value of class IV. Missing
PGA values due to death were imputed as ‘died’ and missing PGA values
due to hospitalization were imputed as ‘much worse’.
ANCOVA repeated measure models were used for the analysis of
the continuous secondary end-points variables, and repeated measures
polytomous regression for the non-continuous variables analysis.
Time-to-event analyses were conducted using Kaplan–Meier estimators
and log-rank tests. Hazard ratios (HRs) and corresponding 95% confi-
dence intervals (CIs) were obtained from the proportional hazard ratio
models. Post hoc sensitivity analyses included time-to-event analyses on
composite end-points for death and any first hospitalization, death and
first hospitalization for any cardiovascular reason or death and first hos-
pitalization due to worsening HF. Further post hoc sensitivity analyses
were conducted on the secondary end-point of hospitalization events
due to worsening HF using negative binomial regression models where
incidence rate ratios between treatment groups the 95% CIs and
P-values were calculated.19,20
Safety analyses by summary statistics were performed on all subjects
who received at least one dose of investigational drug or placebo. Follow-
up for collection of key safety information was until 30 days after the end
of the study, i.e. longer than for the efficacy information. Subjects were
analysed according to the treatment they actually received.
Results
In total, 304 patients were enrolled (FCM, 152; placebo, 152) at 41
sites across 9 countries (Austria, Italy, Poland, Portugal, Russia,
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Spain, Sweden, UK, Ukraine). All randomized patients received at
least one dose of study treatment (Figure 1). Three out of the 304 ran-
domized patients were excluded from the FAS for efficacy analyses
due to lack of any post-baseline efficacy assessment, but had contin-
ued in the study (note: none of these three patients had a hospitaliza-
tion or death event). The clinical characteristics of these 301 patients
are presented in Table 1. Baseline clinical and laboratory characteris-
tics and the use of various cardiac medications at the time of enrol-
ment were similar between the two treatment groups.
Follow-up
Of the 150 patients assigned to FCM, 29 (19.3%) patients did not
complete the study of whom 12 (8.0%) patients died. Of the 151
patients assigned to placebo, 24 (15.9%) patients did not complete
the study of whom 14 (9.3%) patients died. Two patients from the
placebo group were lost to follow-up (Figure 1). One patient from
the FCM group died within the 30 day safety follow-up period after
completing the study.
Primary end-point
Baseline values [mean (SD)] of 6MWT distancewere similar between
treatment groups [288 (98) m vs. 302 (97) m, respectively, FCM vs.
placebo]. At Week 24, in the FCM an increase in 6MWT distance
by 18+8 m was detected, whereas in the placebo group there
was a decrease in 6MWT distance by 16+8 m (both least squares
mean+ standard error). It resulted in a significant difference in
changes in 6MWT distance at Week 24 in FCM vs. placebo of
33+ 11 m (least squares mean+ standard error) , P ¼ 0.002.
Secondary end-points
The use of FCM, when compared with placebo, showed a significant
benefit in PGA from Week 12 onwards (P ¼ 0.035 at Week 12,
P ¼ 0.047 at Week 24, and P ¼ 0.001 at Weeks 36 and 52) and
NYHA class from Week 24 onwards (P ¼ 0.004 at Week 24 and
P, 0.001 at Weeks 36 and 52) (Figure 2A and B). By using a repeated
measures, model significant improvements were also seen in the dif-
ferences in changes in 6MWT distance at Weeks 36 (42 m with 95%
Figure 1 Enrolment and outcomes. The full analysis set comprised all patients who received at least one dose of randomized treatment and
attended at least one post-baseline visit. The safety population included all patients who received at least one dose of randomized treatment. Sup-
portive analyses were performed using the per-protocol set (those subjects who participated in the trial included in the full-analysis set without
major protocol violations).
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CI of 21–62, p, 0.001) and Weeks 52 (36 m with 95% CI of 16–57,
p , 0.001) (Figure 3A). Significant reductions in the Fatigue Score
were observed from Week 12 onwards (P ¼ 0.009 at Week 12,
P ¼ 0.002 at Week 24, and Week 52, P, 0.001 at Week 36) for
the FCM group compared with placebo (Figure 3B). A beneficial
effect on QoL, as evaluated by the overall KCCQ score, was
observed in the FCM group at Weeks 12, 36, and 52 (P, 0.05 for
all comparisons) (Figure 3C). The EQ-5D health state score showed
a benefit for FCM over placebo throughout the study but achieved
significance only at Week 36 (P ¼ 0.002) (Figure 3D).
During the study, 76 patients werehospitalized at least once [FCM:
32 (21%), placebo: 44 (29%) patients]. The time-to-event analysis
indicated an HR of 0.71 with a 95% CI of (0.45–1.12) (P ¼ 0.14)
(Table 2). There were 46 hospitalizations for any reason in the
FCM group and 69 in the placebo group. Treatment with FCM was
associated with a significant reduction in the risk of hospitalization
due to worsening HF with a time-to-event analysis returning an HR
of 0.39 with a 95% CI of (0.19–0.82) (P ¼ 0.009) (Table 2, Figure 4).
The incidence of all-cause death was similar in both groups (FCM:
8.9, placebo: 9.9 per 100 patient-year at risk) (Table 2).
In post hoc sensitivity analysis, we found that the combined risk of
first hospitalization due to worsening HF or all-cause death was sig-
nificantly lower in the FCM group [HR (95% CI): 0.53 (0.30–0.95),
P ¼ 0.03] (Table 2). The post hoc sensitivity analysis of recurrent
events on the number of hospitalizations due to worsening HF
using the negative binomial regression models confirmed positive
treatment effect of FCM with an incidence rate ratio (95% CI) of
0.30 (0.14–0.64), P ¼ 0.0019 compared with placebo (in total 10
hospitalizations due to worsening of HF in the FCM and 32 in the
placebo group during the study).
Laboratory values for serum ferritin, TSAT, and Hb showed an in-
crease in the FCM group at Weeks 24 and 52 and were significantly
different between the two treatment groups (all P, 0.001).
Overall, the mean treatment effect on ferritin and TSAT (adjusted
for baseline) in patients assigned to FCM compared with placebo
was 265+ 19 ng/mL and 8.9+ 1.1% at Week 24, and 200+
19 ng/mL and 5.7+1.2% at Week 52 (all P, 0.001). The corre-
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Table 1 Baseline Demographic and Clinical
Characteristics (FAS)
Variable FCM Placebo
(N5 150) (N5 151)
Mean (SD) Mean (SD)
Age yrs 68.8 (9.5) 69.5 (9.3)
Female sex n (%) 67 ( 45) 74 ( 49)
White race n (%) 149 ( 99) 150 ( 99)
NYHA class n (%)
II 80 ( 53) 91 ( 60)
III 70 ( 47) 60 ( 40)
LVEF % 37.1 (7.5) 36.5 (7.3)
Body Mass kg 78.6 (14.0) 80.8 (18.4)
Body Mass Index kg/m2 28.3 (4.6) 29.1 (5.7)
Blood pressure mm Hg
Systolic 125 (14) 124 (13)
Diastolic 75 (8) 75 (8)
Pulse beats/minute 69 (11) 71 (11)
6-Minute walk test distance m 288 (98) 302 (97)
Ischemic cause of heart failure n (%) 125 ( 83) 126 ( 83)
Quality of Life Assessments
Fatigue score 5.5 (1.6) 5.3 (1.7)
KCCQ score 59.0 (17.3) 58.8 (17.9)
EQ-5D VAS 54.7 (15.0) 54.1 (16.3)
Cardiovascular Risk Factor n (%)
Hypertension 130 ( 87) 130 ( 86)
Dyslipidaemia 98 ( 65) 98 ( 65)
Diabetes mellitus 38 ( 25) 45 ( 30)
Smoking 54 (36) 41 (27)
Medical History n (%)
Atrial fibrillation 66 ( 44) 73 ( 48)
Myocardial infarction 90 ( 60) 90 ( 60)
Angina pectoris 98 ( 65) 91 ( 60)
Stroke 21 ( 14) 24 ( 16)
Coronary revascularization 46 ( 31) 39 ( 26)
Laboratory Measurements
Hb g/dL 12.37 (1.41) 12.42 (1.30)
Ferritin ng/mL 57.0 (48.4) 57.1 (41.6)
, 100 ng/ml n (%) 136 (91) 133 (88)
TSAT % 20.2 (17.6) 18.2 (8.1)
CRP mg/L 5.19 (9.00) 6.00 (11.60)
BNP pg/mL 772 (995) 770 (955)
NT Pro-BNP pg/mL 2511 (5006) 2600 (4555)
Sodium mmol/L 143 (3) 142 (5)
Potassium mmol/L 4.69 (0.54) 4.63 (0.55)
ALT U/L 21.1 (18.9) 18.7 (9.9)
AST U/L 26.2 (19.6) 23.5 (8.6)
eGFR mL/min/1.73m2 66.4 (21.7) 63.5 (20.9)
Continued
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Table 1 Continued
Variable FCM Placebo
(N5 150) (N5 151)
Mean (SD) Mean (SD)
Concomitant treatment n (%)
Diuretic 132 (88) 139 (92)
ACE inhibitor 116 (77) 118 (78)
ARB 34 (23) 37 (25)
Digitalis glycoside 29 (19) 40 (27)
Beta-blocker 133 (89) 139 (92)
Antithrombotic agents 142 (95) 144 (95)
Lipid-lowering therapy 105 (70) 110 (73)
Insulin and analogues 18 (12) 20 (13)
Oral hypoglycaemic agent 26 (17) 32 (21)
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sponding mean differences for Hb (adjusted for baseline) were 0.6+
0.2 and 1.0+0.2 g/dL, at Weeks 24 and 52, respectively (all P,
0.001).
Subgroup analyses
In all subgroups examined, the treatment effect was preserved.
A consistent improvement in 6MWT distance at Week 24 in patients
treated with FCM when compared with placebo was demonstrated.
For the majority of subgroups, there was no significant interaction
(Figure 5). Where the interaction for the subgroups was statistically
significant, i.e. in those with/without diabetes mellitus (P ¼ 0.04)
and impaired/preserved renal function (P ¼ 0.038), the magnitude
of the benefit for FCM over placebo varies, but it is not indicative
of a different direction of effect in any of these subgroups.The original,
pre-specified subgroup for baseline ferritin examined those subjects
with baseline ferritin levels at ,100 or ≥100 ng/mL. However, the
number of subjects in the latter group was very small (14 in the
FCM group and 18 in the placebo group) and made the results of
this analysis uninterpretable. Therefore, we examined subjects with
baseline ferritin above and below the median ferritin value as a post
hoc analysis (Figure 5).
In the primary efficacy analysis adjustment for country (Russia,
Ukraine, Poland considered separately, and other European
countries pooled together) revealed no significant interaction
(P ¼ 0.30), which indicates that treatment effect on 6MWT at
Week 24 is consistent without major regional outliers.
Figure 2 Patient Global Assessment and NYHA Functional Class over Time (full-analysis set). The data presented are odds ratios for patient
global assessment (A) and NYHA functional class (B) for the ferric carboxymaltose group when compared with the placebo, of being in a better
category of patient global assessment (A) and NYHA functional class (B). In those panels, the P-values are for the comparison between the two
study groups, and the I bars denote the 95% confidence intervals.
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Figure3 6-MinWalkTest, FatigueandQualityof Life ScoreoverTime(full-analysis set). Shownaredata across the studyperiodusinga repeatmeasures
model for the changes (least squares mean with the 95% confidence intervals on the 6-min walk test (A), Fatigue score (assessed using a 10-point visual
analogue fatigue scale, ranging from 1 for no fatigue to 10 for very severe fatigue) shown in (B), Kansas City Cardiomyopathy questionnaire (KCCQ)
score (on which the overall score ranges from 0 to 100, with a higher score indicating a better QoL) shown in (C), and the European Quality of Life-5
Dimensions (EQ-5D) Visual Analogue Scale (on which the score ranges from 0 to 100, with higher scores indicating better health) shown in (D).
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Safety analyses
The overall incidence of investigator reported adverse events,
serious adverse events and adverse events leading to study discon-
tinuation were similar in both groups (Table 3).
No severe allergic reactions related to the study treatment were
reported. Of the patients reporting treatment-related adverse
events with FCM, two patients experienced injection site discolour-
ation, four patients reported feeling hot, and skin discolouration,
urticaria, rash, and erythema were each reported by one patient.
No differences were observed between the two treatment groups
with respect to investigator reported adverse events related to
laboratory test results.
Dosing
In the FCM arm, the mean and median total dose was 1500 mg
of iron during the 1-year study period, with a dosing range of
500–3500 mg of iron. Over 75% of the patients required a
maximum of two injections of FCM to correct and maintain
the iron parameters.
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Table 2 Hospitalizations and deaths (full-analysis set)
End-point or event FCM (n 5 150) Placebo (n5 151)
Total
number of
events
Incidence/100
patient-yearsat risk
Total
number of
events
Incidence/100
patient- years at
risk
Time to first event
hazard ratio 95% CI
P-value
Death 12 12 (8.9) 14 14 (9.9) 0.89 (0.41– 1.93) 0.77
Death for any cardiovascular
reason
11 11 (8.1) 12 12 (8.5) 0.96 (0.42– 2.16) 0.91
Death due to worsening HF 4 4 (3.0) 3 3 (2.1) 1.39 (0.31–6.21) 0.67
Death due to other
cardiovascular reason
7 7 (5.2) 9 9 (6.4) 0.81 (0.30–2.17) 0.68
Hospitalizations 46 32 (26.3) 69 44 (37.0) 0.71 (0.45–1.12) 0.14
Hospitalizations for any
cardiovascular reason
26 21 (16.6) 51 33 (26.3) 0.63 (0.37–1.09) 0.097
Hospitalizations due to
worsening HF
10 10 (7.6) 32 25 (19.4) 0.39 (0.19–0.82) 0.009
Hospitalizations due to other
cardiovascular reason
16 13 (10.0) 19 15 (11.0) 0.91 (0.43–1.92) 0.81
Post hoc Analyses
Hospitalizations or death 58 38 (31.2) 83 50 (42.1) 0.75 (0.49–1.14) 0.17
Hospitalizations for any
cardiovascular reason or
death
38 28 (22.1) 65 40 (31.9) 0.70 (0.43–1.13) 0.14
Hospitalizations due to
worsening HF or death
22 18 (13.7) 46 33 (25.6) 0.53 (0.30–0.95) 0.03
Hospitalizations due to other
cardiovascular reason or
death
28 23 (17.7) 33 25 (18.3) 0.97 (0.55–1.70) 0.91
Hospitalizations or death for
any cardiovascular reason
37 27 (21.3) 63 38 (30.3) 0.71 (0.43–1.16) 0.16
Incidence/100 patient-years at risk are computed using the number of subjects with the end-point/event adjusted on the total length of exposure while the subjects are still at risk
[before observing the first event or before completing the study for subjects without any event (censored)].
Figure 4 Time to first hospitalization due to worsening heart
failure. The time to first hospitalization due to worsening heart
failure was estimated using the Kaplan–Meier method, on the full-
analysis set. Subjects were censored at their death, study comple-
tion, or withdrawal date.
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Discussion
The CONFIRM-HF study shows that the treatment of stable, symp-
tomatic, iron-deficient HF patients with i.v. iron (FCM) results in sus-
tainable improvement in functional capacity as measured over a
1-year period using the 6-MWT walking test. These favourable
results were consistent across all pre-specified subgroups including
patients with and without anaemia. The beneficial effects of
treatment with FCM were confirmed by concomitant improvement
in patients functional status and quality of life throughout the study.
Importantly, patients treated with FCM demonstrated significantly
reduced risk of hospital admission due to worsening HF during
1-year follow-up. Long-term correction of ID with FCM was
supported by a good safety profile and was well-tolerated.
Current guidelines of the European Society of Cardiology for the
management of HF recognize ID as a common and clinically relevant
Figure 5 Subgroup analyses for 6-Min Walk Test. Shown are data of 6MWT distance change from baseline to Week 24 analysis results, using
ANCOVA analyses with each subgroup as a covariate, and treatment and the interaction between treatment and subgroup as covariates. The
least squares mean of the difference between ferric carboxymaltose and placebo groups and the 95% confidence intervals are displayed for each
subgroup. The P-values of the interaction term (treatment and subgroups) are presented.
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comorbidity, complicating the natural course of the disease, and rec-
ommend to actively search for this abnormality using laboratory
parameters in all patients with HF.2 At the same time, there is a rela-
tively weaker recommendation to manage ID in such patients, which
mainly results from a paucity of evidence-based data confirming the
benefits of iron therapy.2,14 In fact, there is only one medium-size,
double-blind, placebo-controlled clinical trial (FAIR-HF) showing
beneficial effects of i.v. iron therapy with FCM on functional status,
exercise intolerance and QoL in ID patients with HF over a
6-month follow-up period.18 There is no doubt that for a stronger
recommendation of ID as a valid therapeutic target in HF, additional
well-designed and controlled studies with longer follow-up period
are needed. To this end, CONFIRM-HF was designed and executed.
Noteworthy, the results of CONFIRM-HF should be viewed as
adding incremental and clinically relevant information over already
existing data in the following aspects:
(a) selection of a different and—compared with FAIR-HF—more
objective primary end-point (changes in 6MWT distance) in
order to use more robust method for the assessment of the
clinical status of HF patients;
(b) documenting longer-term sustainability of beneficial effects of
treatment with FCM with acceptable safety profile (i.e. for 12
months compared with 6 months or less in prior studies);
(c) providing intriguing data on significant risk reduction of the
hospitalization due to HF worsening;
(d) offering a simplified and more clinically applicable method of ID
therapy with FCM.
All these aspects will be briefly discussed below.
In FAIR-HF, the primary end-point was based on the evaluation of
NYHA class and PGA.18 In CONFIRM-HF, we chose changes in
6MWT distance as the primary end-point, because it is a more
robust method assessing the clinical status of HF patients.21,22 The
6MWT is a well-established, reproducible method for the assess-
ment of functional capacity, sensitive to changes in self-reported
symptoms,22 which has been previously used in numerous HF
studies evaluating the effects of different interventions.23 We
expected, that by targeting ID, which impedes oxygen transportation
and/or utilization we would be able to improve patients’ exercise tol-
erance.15 Our results demonstrate indeed, that therapy with FCM
significantly improved patients’ functional capacity. Beneficial
effects of FCM were already seen at Weeks 6 and 12 (strong trend
favouring FCM), reaching statistical significance at Week 24 and
were sustained until the end of 1-year follow-up. The magnitude of
the treatment effect of FCM on the 6MWT distance, exceeding
30 m in the last 6-month study period, is robust and clinically mean-
ingful. In previous interventional studies, such beneficial effects have
only been seen with cardiac resynchronization therapy.23 Important-
ly, improvement in6MWTdistancewas seenacross all examinedsub-
groups, including patients with and without anaemia, which further
challenges the traditional view linking adverse consequences of ID
with anaemia. Cardiopulmonaryexercise testing with the assessment
of peak oxygen consumption is another method applied to evaluate
functional capacity in HF, which can provide even more objective
information on exercise tolerance than 6MWT. Currently, there is
an ongoing clinical trial using this method (www.clinicaltrial.gov:
EFFECT-HF, NCT01394562), which will provide complementary
information on the effects i.v. iron therapy with FCM in
iron-deficient HF patients.
Patients included in this study represent a contemporary popula-
tion of stable, systolic HF with optimized medical management. Of
importance, compared with the FAIR-HF study, we recruited
nearly equal numbers of patients in NYHA class II and III (compared
with 18% NYHA class II patients in FAIR-HF) with higher LVEF
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Table 3 List of adverse events (safety amalysis set)
Safety end-point or event FCM (n5 152) n (%) events Placebo (n5 152) n (%) events
Subjects with at least one AE 121 (79.6) 555 115 (75.7) 547
Subject with at least one severe AE 21 (13.8) 31 27 (17.8) 54
Subject with at least one serious AE 43 (28.3) 68 53 (34.9) 106
Subject with at least one AE leading to study drug withdrawal 14 (9.2) 14 19 (12.5) 19
Subject with at least one severe drug-related AE 0 (0.0) 0 0 (0.0) 0
Subject with at least one serious drug-related AE 0 (0.0) 0 0 (0.0) 0
Subject with at least one drug-related leading to study drug withdrawal 1 (0.7) 1 0 (0.0) 0
Subject with at least one drug-related AE 14 (9.2) 24 5 (3.3) 7
General disorders and administration site conditions 9 (5.9) 9 2 (1.3) 2
Skin and subcutaneous tissue disorders 4 (2.6) 4 0 (0.0) 0
Nervous system disorders 2 (1.3) 3 1 (0.7) 1
Gastro-intestinal disorders 2 (1.3) 3 0 (0.0) 0
Vascular disorders 1 (0.7) 2 1 (0.7) 1
Investigations 1 (0.7) 1 2 (1.3) 2
Ear and labyrinth disorders 1 (0.7) 1 0 (0.0) 0
Injury, poisoning and procedural complications 1 (0.7) 1 0 (0.0) 0
Cardiac disorders 0 (0.0) 0 1 (0.7) 1
n, number of subjects experiencing at least one time the considered event; %, percentage of above in the total number of subjects in the group; events, total number of events.
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(mean LVEF—37 vs. 32% in FAIR-HF). The benefit was seen regard-
less of clinical severity (as evidenced by no interaction between
NYHA class, LVEF and BNP level with treatment effect), which
further broadens the clinical applicability of our results.
In the subgroup analyses, the presence of diabetes and impaired
renal function interacted with treatment effects. However, these
interactions are not for the direction of effect but only for its magni-
tude (with a greater benefit for sicker patients with diabetes and
impaired renal function). Interestingly, these findings may have
important clinical implications allowing us to identify HF patients
who could potentially benefit most from i.v. iron therapy. Of note,
it has recently been demonstrated that ID is common in patients
with coronary artery disease with concomitant type 2 diabetes mel-
litus and independently predicts poor outcome.9 Heart failure
patients with renal dysfunction are prone to develop ID, which
often coincides with low-Hb level.24 Therapy with i.v. iron is able
to correct these ominous abnormalities. Interestingly, Toblli et al.25
demonstrated that in anaemic HF patients with ID and renal dysfunc-
tion, short-term i.v. iron therapy resulted in significant improvement
in renal function. At this stage, however, these intriguing findings need
to be considered as hypothesis-generating only, and further tested in
prospective clinical trials.
In this study, beneficial effects of ID correction with FCM were
further confirmed by observed improvement in the other indices
of functional capacity (NYHA class, PGA, Fatigue score) as well as
in QoL throughout the whole study period. This is particularly
important, as despite modern improvement in HF management, a
considerable proportion of patients remains symptomatic. Hence,
well-tolerated therapies with good safety profiles, improving symp-
toms in the long-term perspective are eagerly awaited.
In evaluating the effects of new therapies in the settings of chronic
HF one would expect these would improve patients’ clinical status
and QoL, reduce the risk of deterioration (i.e. hospital admission
due to worsening HF), and finally prolong survival. Recently, investi-
gators observed a striking reduction in mortality in patients with
chronic HF with a parallel increase in the hospital admission rate
due to worsening HF.26 As hospitalizations due to worsening HF
are always related to poor outcome and impairment of patient’s
quality of life and constitute an economic burden for society,27
there is evident need for their prevention. In this context, the
results of CONFIRM-HF showing that FCM treatment was related
to a significant risk reduction in first hospital admissions due to wor-
sening HF are of particular interest. Additional analysis taking into
account all recurrent HF hospitalizations showed an even stronger
effect with a rate ratio (FCM vs. placebo) of 0.30. Among recently
introduced pharmacological therapies, only ivabradine28 has demon-
strated such results. Although therewasno difference in the numbers
of deaths between groups, a 1-year follow-up may not be adequate to
detect any mortality difference. We are aware that the study was not
designed primarily to address the morbidity/mortality aspect of ID
therapy with FCM, but our results constitute a strong background
for such a study to be performed in the near future.
As in previous studies,16,18 our patient population was identified
on the basis of laboratory biomarkers of ID—ferritin and TSAT.
However, in contrast to these studies we used a simplified dosing
regimen for FCM recently proposed by Evstatiev et al.29 based on
weight and Hb levels. These authors demonstrated that this
simplified dosing regimen is superior in efficacy to dosing using the
traditional Ganzoni formula30 with an accompanying good safety
profile. In the FCM arm, the median total dose was 1500 mg of iron
during the 1-year study period (with a dosing range of 500–
3500 mg iron) and over 75% of the patients required a maximum
of two injections of FCM to correct ID and maintain the iron para-
meters within the normal range. Additionally, we extended the pre-
viousexperiencewith FCMtherapy in non-anaemic ID patientswhich
included patients with Hb levels between 9.5 and 13.5 g/dL,18 whereas
in this study only patients with Hb values .15 g/dL were excluded.
In most of the recent studies, ID in HF patients has been cor-
rected using i.v. iron with favourable results. Thus, a relevant ques-
tion arises, whether similar results would be observed with oral iron
therapy. This complex problem remains as yet poorly investigated
and unanswered. There are several premises favouring i.v. iron
and practicality seems to be the most obvious one. To replete ID
in HF, which is typically estimated in a range exceeding 1000 mg,
several months of oral therapy would be required with subsequent
risk of poor tolerance. In contrast, with FCM as studied in FAIR-HF
and CONFIRM-HF, a low risk of adverse effects is observed and only
few injections are needed to treat ID (in CONFIRM-HF over 75% of
the patients required a maximum of two injections of FCM to
correct and maintain iron therapy). Recent experimental evidence
demonstrates disrupted regulatory mechanisms of duodenal iron
transportation systems in animals with induced HF and ID.31 On
the other hand, iron absorption has never been investigated in HF
patients, and whether the phenomena described in rodents would
play any role in a clinical setting of HF is entirely unknown. It is
also tempting to link ID in HF with inflammation, and to hypothesize
about the leading role of elevated hepcidin, which also blocks iron
absorption. Recent studies, however, report rather low-hepcidin
levels in HF patients and no association between pro-inflammatory
activation (as evidenced by circulating IL-6) and hepcidin
levels.13,32,33 There is only one small clinical study showing the ad-
vantage of i.v. iron therapy over oral iron on exercise capacity in
anaemic iron-deficient HF patients,34 but with only 18 subjects ana-
lysed it is far from being conclusive. Therefore, there is a need to
evaluate the efficacy of oral iron therapy in iron-deficient HF
patients in adequately large, prospective, randomized clinical trial.
To our knowledge such a trial is planned (www.clinicaltrial.gov:
IRONOUT, NCT02188784).
In conclusion, treatment of stable, symptomatic, iron-deficient
HF patients with ferric carboxymaltose over a 1-year period results
in sustained improvement in functional capacity, symptoms and
quality of life, and may reduce hospitalizations due to worsening HF.
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